TrialJournal of hematology & oncology2025

Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial.

Gang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.